《中国胰腺癌新辅助治疗指南(2020版)》解读

Interpretation of the guidelines for neoadjuvant therapy of pancreatic cancer in China(2020 edition)

胰腺癌是高度恶性的消化系统肿瘤,预后极差。随着对胰腺癌生物学行为认识的不断深入及综合治疗理念的普及,新辅助治疗在胰腺癌治疗中的作用日益凸显。中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会联合制定了《中国胰腺癌新辅助治疗指南(2020版)》,就胰腺癌新辅助治疗中的关键问题进行系统全面的阐述,为胰腺癌新辅助治疗的临床实践提供了参考依据。本文对指南中的新辅助治疗前准备、指征把握、方案选择、新辅助治疗后的再评估及手术策略等方面的内容进行解读,进一步探讨胰腺癌新辅助治疗存在的争议。

Pancreatic cancer is a highly malignant tumor in the digestive system.The role of neoadjuvant therapy in pancreatic cancer has been highlighted with the understanding of pancreatic cancer biological behavior and popularization of comprehensive treatment.Therefore,Study group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association has formulated the guidelines for neoadjuvant therapy of pancreatic cancer in China(2020 edition).This guidelines elaborated key issues of the neoadjuvant therapy of pancreatic cancer,and provided reference for clinical practice.This article aims to interpret the guidelines about the preparation before neoadjuvant therapy,indication,regimen selection,therapeutic effect evaluation and surgery strategy,with further discussion about controversial issues of neoadjuvant therapy in pancreatic cancer.